Search for a doctor

Joseph H. Butterfield, M.D.

  1. Allergist-Immunologist
  2. Internist
Request an Appointment

Publications

  1. Butterfield JH, Taylor A. Acute/baseline ratios of all 3 MC mediator metabolites can enhance diagnosis and management of mast cell activation syndrome. J Allergy Clin Immunol Glob. 2025 May; 4 (2):100399 Epub 2024 Dec 28
    View PubMed
  2. Valent P, Hartmann K, Hoermann G, Reiter A, Alvarez-Twose I, Brockow K, Bonadonna P, Hermine O, Niedoszytko M, Carter MC, Butterfield JH, Siebenhaar F, Zanotti R, Radia DH, Castells M, Sperr WR, Broesby-Olsen S, Triggiani M, Schwartz LB, George TI, Gulen T, Sotlar K, Gotlib J, Galli SJ, Horny HP, Metcalfe DD, Orfao A, Arock M, Akin C. Harmonization of Diagnostic Criteria in Mastocytosis for Use in Clinical Practice: WHO vs ICC vs AIM/ECNM. J Allergy Clin Immunol Pract. 2024 Dec; 12 (12):3250-3260.e5 Epub 2024 Aug 30
    View PubMed
  3. Castells M, Giannetti MP, Hamilton MJ, Novak P, Pozdnyakova O, Nicoloro-SantaBarbara J, Jennings SV, Francomano C, Kim B, Glover SC, Galli SJ, Maitland A, White A, Abonia JP, Slee V, Valent P, Butterfield JH, Carter M, Metcalfe DD, Akin C, Lyons JJ, Togias A, Wheatley L, Milner JD. Mast cell activation syndrome: Current understanding and research needs. J Allergy Clin Immunol. 2024 Aug; 154 (2):255-263 Epub 2024 June 06
    View PubMed
  4. Butterfield JH, Bartemes K. Metformin: A potential adjunct for treatment of systemic mastocytosis. J Allergy Clin Immunol Glob. 2024 Feb; 3 (1):100186 Epub 2023 Nov 07
    View PubMed
  5. Valent P, Hoermann G, Bonadonna P, Hartmann K, Sperr WR, Broesby-Olsen S, Brockow K, Niedoszytko M, Hermine O, Chantran Y, Butterfield JH, Greiner G, Carter MC, Sabato V, Radia DH, Siebenhaar F, Triggiani M, Gulen T, Alvarez-Twose I, Staudinger T, Traby L, Sotlar K, Reiter A, Horny HP, Orfao A, Galli SJ, Schwartz LB, Lyons JJ, Gotlib J, Metcalfe DD, Arock M, Akin C. The Normal Range of Baseline Tryptase Should Be 1 to 15 ng/mL and Covers Healthy Individuals With HalphaT. J Allergy Clin Immunol Pract. 2023 Oct; 11 (10):3010-3020 Epub 2023 Aug 10
    View PubMed
  6. Lau S, Sprung J, Volcheck GW, Butterfield JH, Divekar RD, Weingarten TN. Perioperative management of mastocytosis. J Anesth. 2023 Oct; 37 (5):741-748 Epub 2023 July 19
    View PubMed
  7. Butterfield JH. Increased Excretion of Mast Cell Mediator Metabolites During Mast Cell Activation Syndrome. J Allergy Clin Immunol Pract. 2023 Aug; 11 (8):2542-2546 Epub 2023 Feb 28
    View PubMed
  8. Zayas J, Peters MS, Butterfield JH, Pongdee T, Sokumbi O. Clinical and histopathological features of hypereosinophilic syndrome with cutaneous involvement: The Mayo Clinic Experience. J Cutan Pathol. 2023 May; 50 (5):455-465 Epub 2023 Mar 03
    View PubMed
  9. Roufosse F, Butterfield J, Steinfeld J, Bentley JH, von Maltzahn R, Kwon N, Nelsen L. Mepolizumab therapy improves the most bothersome symptoms in patients with hypereosinophilic syndrome. Front Med (Lausanne). 2023; 10:1035250 Epub 2023 Mar 29
    View PubMed
  10. Valent P, Klion AD, Roufosse F, Simon D, Metzgeroth G, Leiferman KM, Schwaab J, Butterfield JH, Sperr WR, Sotlar K, Vandenberghe P, Hoermann G, Haferlach T, Moriggl R, George TI, Akin C, Bochner BS, Gotlib J, Reiter A, Horny HP, Arock M, Simon HU, Gleich GJ. Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes. Allergy. 2023 Jan; 78 (1):47-59 Epub 2022 Oct 19
    View PubMed
  11. Giannetti MP, Godwin G, Weller E, Butterfield JH, Castells M. Differential mast cell mediators in systemic mastocytosis and hereditary alpha-tryptasemia. J Allergy Clin Immunol. 2022 Nov; 150 (5):1225-1227 Epub 2022 May 09
    View PubMed
  12. Valent P, Hartmann K, Schwaab J, Alvarez-Twose I, Brockow K, Bonadonna P, Hermine O, Niedoszytko M, Carter MC, Hoermann G, Sperr WR, Butterfield JH, Ustun C, Zanotti R, Radia DH, Castells M, Triggiani M, Schwartz LB, Orfao A, George TI, Sotlar K, Gotlib J, Reiter A, Horny HP, Arock M, Akin C, Metcalfe DD. Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM User's Guide for Daily Clinical Practice. J Allergy Clin Immunol Pract. 2022 Aug; 10 (8):1999-2012.e6 Epub 2022 Mar 25
    View PubMed
  13. Butterfield JH. Nontryptase Urinary and Hematologic Biomarkers of Mast Cell Expansion and Mast Cell Activation: Status 2022. J Allergy Clin Immunol Pract. 2022 Aug; 10 (8):1974-1984 Epub 2022 Mar 26
    View PubMed
  14. Hoermann G, Sotlar K, Jawhar M, Kristensen T, Bachelot G, Nedoszytko B, Carter MC, Horny HP, Bonadonna P, Sperr WR, Hartmann K, Brockow K, Lyons JJ, Kluin-Nelemans HC, Hermine O, Akin C, Broesby-Olsen S, Triggiani M, Butterfield JH, Schwaab J, Reiter A, Gotlib J, Metcalfe DD, George TI, Orfao A, Valent P, Arock M. Standards of Genetic Testing in the Diagnosis and Prognostication of Systemic Mastocytosis in 2022: Recommendations of the EU-US Cooperative Group. J Allergy Clin Immunol Pract. 2022 Aug; 10 (8):1953-1963 Epub 2022 Mar 11
    View PubMed
  15. Gotlib J, Schwaab J, Shomali W, George TI, Radia DH, Castells M, Carter MC, Hartmann K, Alvarez-Twose I, Brockow K, Bonadonna P, Hermine O, Niedoszytko M, Hoermann G, Sperr WR, Elberink HO, Siebenhaar F, Butterfield JH, Ustun C, Zanotti R, Triggiani M, Schwartz LB, Lyons JJ, Orfao A, Sotlar K, Horny HP, Arock M, Metcalfe DD, Akin C, Lubke J, Valent P, Reiter A. Proposed European Competence Network on Mastocytosis-American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic Mastocytosis. J Allergy Clin Immunol Pract. 2022 Aug; 10 (8):2025-2038.e1 Epub 2022 June 18
    View PubMed
  16. Sotlar K, George TI, Kluin P, Reiter A, Schwaab J, Panse J, Brockow K, Hartmann K, Sperr WR, Kristensen T, Nedoszytko B, Carter M, Bonadonna P, Lyons JJ, Kluin-Nelemans HC, Hermine O, Akin C, Broesby-Olsen S, Hoermann G, Triggiani M, Butterfield JH, Jawhar M, Gotlib J, Metcalfe DD, Orfao A, Arock M, Valent P, Horny HP. Standards of Pathology in the Diagnosis of Systemic Mastocytosis: Recommendations of the EU-US Cooperative Group. J Allergy Clin Immunol Pract. 2022 Aug; 10 (8):1986-1998.e2 Epub 2022 June 18
    View PubMed
  17. Pyatilova P, Akin C, Alvarez-Twose I, Arock M, Bonadonna P, Brockow K, Butterfield JH, Broesby-Olsen S, Carter MC, Castells M, George TI, Gotlib J, Greiner G, Gulen T, Hartmann K, Hermine O, Horny HP, Jawhar M, Lange M, Lyons JJ, Maurer M, Metcalfe DD, Nedoszytko B, Niedoszytko M, Orfao A, Reiter A, Schwaab J, Sotlar K, Sperr WR, Triggiani M, Valent P, Siebenhaar F. Refined Treatment Response Criteria for Indolent Systemic Mastocytosis Proposed by the ECNM-AIM Consortium. J Allergy Clin Immunol Pract. 2022 Aug; 10 (8):2015-2024 Epub 2022 June 18
    View PubMed
  18. Valent P, Hartmann K, Bonadonna P, Gulen T, Brockow K, Alvarez-Twose I, Hermine O, Niedoszytko M, Carter MC, Hoermann G, Butterfield JH, Lyons JJ, Sperr WR, Greiner G, Sotlar K, Kluin-Nelemans HC, Schwaab J, Lange M, George TI, Siebenhaar F, Broesby-Olsen S, Jawhar M, Nedoszytko B, Castells M, Orfao A, Gotlib J, Reiter A, Horny HP, Triggiani M, Arock M, Metcalfe DD, Akin C. Global Classification of Mast Cell Activation Disorders: An ICD-10-CM-Adjusted Proposal of the ECNM-AIM Consortium. J Allergy Clin Immunol Pract. 2022 Aug; 10 (8):1941-1950 Epub 2022 May 25
    View PubMed
  19. Chen MM, Roufosse F, Wang SA, Verstovsek S, Durrani SR, Rothenberg ME, Pongdee T, Butterfield J, Lax T, Wechsler ME, Stein ML, Ogbogu PU, Kahwash BM, Mathur SK, Simon D, Akuthota P, Holland N, Wetzler L, Ware JM, Guo C, Fay MP, Khoury P, Klion AD, Bochner BS. An International, Retrospective Study of Off-Label Biologic Use in the Treatment of Hypereosinophilic Syndromes. J Allergy Clin Immunol Pract. 2022 May; 10 (5):1217-1228.e3 Epub 2022 Feb 15
    View PubMed
  20. Gotlib J, Schwaab J, Shomali W, George TI, Radia DH, Castells M, Carter MC, Hartmann K, Alvarez-Twose I, Brockow K, Bonadonna P, Hermine O, Niedoszytko M, Hoermann G, Sperr WR, Elberink HO, Siebenhaar F, Butterfield JH, Ustun C, Zanotti R, Triggiani M, Schwartz LB, Lyons JJ, Orfao A, Sotlar K, Horny HP, Arock M, Metcalfe DD, Akin C, Lubke J, Valent P, Reiter A. Proposed European competence network on mastocytosis--American initiative in mast cell diseases (ECNM-AIM) response criteria in advanced systemic mastocytosis. Journal of Allergy and Clinical Immunology. In Practice. 2022; 10 (8):2025-38.e1
  21. Valent P, Akin C, Hartmann K, Alvarez-Twose I, Brockow K, Hermine O, Niedoszytko M, Schwaab J, Lyons JJ, Carter MC, Elberink HO, Butterfield JH, George TI, Greiner G, Ustun C, Bonadonna P, Sotlar K, Nilsson G, Jawhar M, Siebenhaar F, Broesby-Olsen S, Yavuz S, Zanotti R, Lange M, Nedoszytko B, Hoermann G, Castells M, Radia DH, Munoz-Gonzalez JI, Sperr WR, Triggiani M, Kluin-Nelemans HC, Galli SJ, Schwartz LB, Reiter A, Orfao A, Gotlib J, Arock M, Horny HP, Metcalfe DD. Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal. Hemasphere. 2021 Nov; 5 (11):e646 Epub 2021 Oct 13
    View PubMed
  22. Gulen T, Akin C, Bonadonna P, Siebenhaar F, Broesby-Olsen S, Brockow K, Niedoszytko M, Nedoszytko B, Oude Elberink HNG, Butterfield JH, Sperr WR, Alvarez-Twose I, Horny HP, Sotlar K, Schwaab J, Jawhar M, Zanotti R, Nilsson G, Lyons JJ, Carter MC, George TI, Hermine O, Gotlib J, Orfao A, Triggiani M, Reiter A, Hartmann K, Castells M, Arock M, Schwartz LB, Metcalfe DD, Valent P. Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review. J Allergy Clin Immunol Pract. 2021 Nov; 9 (11):3918-3928 Epub 2021 June 22
    View PubMed
  23. Butterfield JH, Singh RJ. Divergent PGD(2) and leukotriene C(4) metabolite excretion following aspirin therapy: Ten patients with systemic mastocytosis. Prostaglandins Other Lipid Mediat. 2021 Aug; 155:106563 Epub 2021 May 21
    View PubMed
  24. Bonadonna P, Brockow K, Niedoszytko M, Elberink HO, Akin C, Nedoszytko B, Butterfield JH, Alvarez-Twose I, Sotlar K, Schwaab J, Jawhar M, Castells M, Sperr WR, Hermine O, Gotlib J, Zanotti R, Reiter A, Broesby-Olsen S, Bindslev-Jensen C, Schwartz LB, Horny HP, Radia D, Triggiani M, Sabato V, Carter MC, Siebenhaar F, Orfao A, Grattan C, Metcalfe DD, Arock M, Gulen T, Hartmann K, Valent P. COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM). J Allergy Clin Immunol Pract. 2021 Jun; 9 (6):2139-2144 Epub 2021 Apr 05
    View PubMed
  25. Gotlib J, George TI, Carter MC, Austen KF, Bochner B, Dwyer DF, Lyons JJ, Hamilton MJ, Butterfield J, Bonadonna P, Weiler C, Galli SJ, Schwartz LB, Elberink HO, Maitland A, Theoharides T, Ustun C, Horny HP, Orfao A, Deininger M, Radia D, Jawhar M, Kluin-Nelemans H, Metcalfe DD, Arock M, Sperr WR, Valent P, Castells M, Akin C. Proceedings from the Inaugural American Initiative in Mast Cell Diseases (AIM) Investigator Conference. J Allergy Clin Immunol. 2021 Jun; 147 (6):2043-2052 Epub 2021 Mar 11
    View PubMed
  26. Butterfield JH. Successful Long-Term Control of the Syndrome of Episodic Angioedema With Eosinophilia (Gleich Syndrome) With Low-Dose Imatinib Mesylate and Prednisone. J Investig Med High Impact Case Rep. 2021 Jan-Dec; 9:2324709620987691
    View PubMed
  27. Butterfield JH, Graham RP. Eosinophilic abscess of the small intestine in treatment-resistant transmural eosinophilic gastroenteritis Clin Case Rep J. 2020; 1(6):1-2.
  28. Butterfield J, Weiler CR. The Utility of Measuring Urinary Metabolites of Mast Cell Mediators in Systemic Mastocytosis and Mast Cell Activation Syndrome. J Allergy Clin Immunol Pract. 2020 Sep; 8 (8):2533-2541 Epub 2020 Mar 03
    View PubMed
  29. Valent P, Akin C, Bonadonna P, Brockow K, Niedoszytko M, Nedoszytko B, Butterfield JH, Alvarez-Twose I, Sotlar K, Schwaab J, Jawhar M, Reiter A, Castells M, Sperr WR, Kluin-Nelemans HC, Hermine O, Gotlib J, Zanotti R, Broesby-Olsen S, Horny HP, Triggiani M, Siebenhaar F, Orfao A, Metcalfe DD, Arock M, Hartmann K. Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic: Expert opinions. J Allergy Clin Immunol. 2020 Aug; 146 (2):300-306 Epub 2020 June 17
    View PubMed
  30. Butterfield JH. Survey of Mast Cell Mediator Levels from Patients Presenting with Symptoms of Mast Cell Activation. Int Arch Allergy Immunol. 2020; 181 (1):43-50 Epub 2019 Nov 13
    View PubMed
  31. Weiler CR, Austen KF, Akin C, Barkoff MS, Bernstein JA, Bonadonna P, Butterfield JH, Carter M, Fox CC, Maitland A, Pongdee T, Mustafa SS, Ravi A, Tobin MC, Vliagoftis H, Schwartz LB. AAAAI Mast Cell Disorders Committee Work Group Report: Mast cell activation syndrome (MCAS) diagnosis and management. J Allergy Clin Immunol. 2019 Oct; 144 (4):883-896 Epub 2019 Aug 30
    View PubMed
  32. Valent P, Akin C, Bonadonna P, Hartmann K, Brockow K, Niedoszytko M, Nedoszytko B, Siebenhaar F, Sperr WR, Oude Elberink JNG, Butterfield JH, Alvarez-Twose I, Sotlar K, Reiter A, Kluin-Nelemans HC, Hermine O, Gotlib J, Broesby-Olsen S, Orfao A, Horny HP, Triggiani M, Arock M, Schwartz LB, Metcalfe DD. Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome. J Allergy Clin Immunol Pract. 2019 Apr; 7 (4):1125-1133.e1 Epub 2019 Feb 05
    View PubMed
  33. Castells M, Butterfield J. Mast Cell Activation Syndrome and Mastocytosis: Initial Treatment Options and Long-Term Management. J Allergy Clin Immunol Pract. 2019 Apr; 7 (4):1097-1106
    View PubMed
  34. Carter MC, Metcalfe DD, Matito A, Escribano L, Butterfield JH, Schwartz LB, Bonadonna P, Zanotti R, Triggiani M, Castells M, Brockow K. Adverse reactions to drugs and biologics in patients with clonal mast cell disorders: A Work Group Report of the Mast Cells Disorder Committee, American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol. 2019 Mar; 143 (3):880-893 Epub 2018 Dec 06
    View PubMed
  35. Valent P, Bonadonna P, Hartmann K, Broesby-Olsen S, Brockow K, Butterfield JH, Triggiani M, Lyons JJ, Oude Elberink JNG, Arock M, Metcalfe DD, Akin C. Why the 20% + 2 Tryptase Formula Is a Diagnostic Gold Standard for Severe Systemic Mast Cell Activation and Mast Cell Activation Syndrome. Int Arch Allergy Immunol. 2019; 180 (1):44-51 Epub 2019 June 28
    View PubMed
  36. Arock M, Wedeh G, Hoermann G, Bibi S, Akin C, Peter B, Gleixner KV, Hartmann K, Butterfield JH, Metcalfe DD, Valent P. Preclinical human models and emerging therapeutics for advanced systemic mastocytosis. Haematologica. 2018 Nov; 103 (11):1760-1771 Epub 2018 July 05
    View PubMed
  37. Bartlett DJ, Childs DS, Breitkopf CR, Grudem ME, Mitchell JL, Looker SA, Ridgeway JL, Lee JL, Butterfield JH, Weroha SJ, Jatoi A. Chemotherapy Acute Infusion Reactions: A Qualitative Report of the Perspectives of Patients With Cancer. Am J Hosp Palliat Care. 2018 Nov; 35 (11):1384-1389 Epub 2018 May 03
    View PubMed
  38. Valent P, Akin C, Bonadonna P, Hartmann K, Broesby-Olsen S, Brockow K, Butterfield JH, Reiter A, Gotlib J, Castells M, Milner JD, Carter MC, Komarow H, Radia D, Pardanani A, Sotlar K, Triggiani M, Horny HP, Arock M, Schwartz LB, Metcalfe DD. Mast cell activation syndrome: Importance of consensus criteria and call for research. J Allergy Clin Immunol 2018 Sep; 142 (3):1008-1010 Epub 2018 June 19
    View PubMed
  39. Butterfield JH, Ravi A, Pongdee T. Mast Cell Mediators of Significance in Clinical Practice in Mastocytosis. Immunol Allergy Clin North Am. 2018 Aug; 38 (3):397-410 Epub 2018 June 09
    View PubMed
  40. Butterfield JH, Kane GC, Weiler CR. Hypereosinophilic syndrome: endomyocardial biopsy versus echocardiography to diagnose cardiac involvement. Postgrad Med. 2017 Jun; 129: (5)517-523.
    View PubMed
  41. Neff BA, Voss SG, Carlson ML, O'Brien EK, Butterfield JH. Treatment of eosinophilic otitis media with pegylated interferon-alpha 2a and 2b. Laryngoscope. 2017 May; 127 (5):1208-1216 Epub 2016 Sept 26
    View PubMed
  42. Patel B, Butterfield JH, Weiler CR, Kane SV. Tolerance and Efficacy with Simultaneous Use of Two Monoclonal Antibodies for a Patient with Hypereosinophilic Syndrome and Ulcerative Colitis. Monoclon Antib Immunodiagn Immunother. 2016 Dec; 35 (6):300-303 Epub 2016 Dec 02
    View PubMed
  43. Chen LT, Chen CT, Jiaang WT, Chen TY, Butterfield JH, Shih NY, Hsu JT, Lin HY, Lin SF, Tsai HJ. BPR1J373, an Oral Multiple Tyrosine Kinase Inhibitor, Targets c-KIT for the Treatment of c-KIT-Driven Myeloid Leukemia. Mol Cancer Ther. 2016 Oct; 15 (10):2323-2333 Epub 2016 Aug 10
    View PubMed
  44. Lueke AJ, Meeusen JW, Donato LJ, Gray AV, Butterfield JH, Saenger AK. Analytical and clinical validation of an LC-MS/MS method for urine leukotriene E4: A marker of systemic mastocytosis. Clin Biochem. 2016 Sep; 49 (13-14):979-82 Epub 2016 Feb 18
    View PubMed
  45. Divekar R, Hagan J, Rank M, Park M, Volcheck G, O'Brien E, Meeusen J, Kita H, Butterfield J. Diagnostic Utility of Urinary LTE4 in Asthma, Allergic Rhinitis, Chronic Rhinosinusitis, Nasal Polyps, and Aspirin Sensitivity. J Allergy Clin Immunol Pract. 2016 Jul-Aug; 4 (4):665-70 Epub 2016 Apr 12
    View PubMed
  46. Molderings GJ, Haenisch B, Brettner S, Homann J, Menzen M, Dumoulin FL, Panse J, Butterfield J, Afrin LB. Pharmacological treatment options for mast cell activation disease. Naunyn Schmiedebergs Arch Pharmacol. 2016 Jul; 389 (7):671-94 Epub 2016 Apr 30
    View PubMed
  47. Motosue MS, Howard MT, Butterfield JH. Rituximab in a patient with splenic marginal zone lymphoma and acquired angioedema. Ann Allergy Asthma Immunol 2016 May; 116 (5):472-3 Epub 2016 Mar 24
    View PubMed
  48. Divekar R, Butterfield J, Maddox D. Successful rapid desensitization to temozolomide: A case series. J Allergy Clin Immunol Pract 2016 May-Jun; 4 (3):545-6 Epub 2016 Jan 20
    View PubMed
  49. Wright BL, Butterfield JH, Leiferman KM, Gleich GJ. Development of eosinophilic endomyocardial disease in a patient with episodic angioedema and eosinophilia. J Allergy Clin Immunol Pract. 2016 Mar-Apr; 4 (2):336-7 Epub 2015 Nov 07
    View PubMed
  50. Hartmann K, Escribano L, Grattan C, Brockow K, Carter MC, Alvarez-Twose I, Matito A, Broesby-Olsen S, Siebenhaar F, Lange M, Niedoszytko M, Castells M, Oude Elberink JNG, Bonadonna P, Zanotti R, Hornick JL, Torrelo A, Grabbe J, Rabenhorst A, Nedoszytko B, Butterfield JH, Gotlib J, Reiter A, Radia D, Hermine O, Sotlar K, George TI, Kristensen TK, Kluin-Nelemans HC, Yavuz S, Hagglund H, Sperr WR, Schwartz LB, Triggiani M, Maurer M, Nilsson G, Horny HP, Arock M, Orfao A, Metcalfe DD, Akin C, Valent P. Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. J Allergy Clin Immunol. 2016 Jan; 137 (1):35-45 Epub 2015 Oct 21
    View PubMed
  51. Butterfield JH, Chen D. Response of patients with indolent systemic mastocytosis to tamoxifen citrate. Leuk Res. 2016 Jan; 40:10-6.
    View PubMed
  52. Afrin LB, Butterfield JH, Raithel M, Molderings GJ. Often seen, rarely recognized: mast cell activation disease--a guide to diagnosis and therapeutic options. Ann Med. 2016; 48: (3)190-201.
    View PubMed
  53. Jin JJ, Butterfield JH, Weiler CR. Hematologic Malignancies Identified in Patients with Hypereosinophilia and Hypereosinophilic Syndromes. J Allergy Clin Immunol Pract. 2015 Nov-Dec; 3: (6)920-5.
    View PubMed
  54. Divekar R, Butterfield J, Butterfield J. Urinary 11beta-PGF2alpha and N-methyl histamine correlate with bone marrow biopsy findings in mast cell disorders. Allergy. 2015 Oct; 70 (10):1230-8 Epub 2015 June 24
    View PubMed
  55. Sprung J, Larson KJ, Divekar RD, Butterfield JH, Schwartz LB, Weingarten TN. Refractory intraoperative hypotension with elevated serum tryptase. Asia Pac Allergy. 2015 Jan; 5 (1):47-50 Epub 2015 Jan 28
    View PubMed
  56. Ravi A, Butterfield J, Weiler CR. Mast cell activation syndrome: improved identification by combined determinations of serum tryptase and 24-hour urine 11beta-prostaglandin2alpha. J Allergy Clin Immunol Pract. 2014 Nov-Dec; 2(6):775-8. Epub 2014 Nov 06.
    View PubMed
  57. Valent P, Sotlar K, Sperr WR, Escribano L, Yavuz S, Reiter A, George TI, Kluin-Nelemans HC, Hermine O, Butterfield JH, Hagglund H, Ustun C, Hornick JL, Triggiani M, Radia D, Akin C, Hartmann K, Gotlib J, Schwartz LB, Verstovsek S, Orfao A, Metcalfe DD, Arock M, Horny HP. Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal. Ann Oncol. 2014 Sep; 25 (9):1691-1700 Epub 2014 Mar 27
    View PubMed
  58. Valent P, Sotlar K, Sperr WR, Escribano L, Yavuz S, Reiter A, George TI, Kluin-Nelemans HC, Hermine O, Butterfield JH, Hagglund H, Ustun C, Hornick JL, Triggiani M, Radia D, Akin C, Hartmann K, Gotlib J, Schwartz LB, Verstovsek S, Orfao A, Metcalfe DD, Arock M, Horny HP. Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal. Ann Oncol. 2014 Sep; 25 (9):1691-1700 Epub 2019 Dec 04
    View PubMed
  59. Weiler CR, Butterfield J. Mast cell sarcoma: clinical management. Immunol Allergy Clin North Am. 2014 May; 34(2):423-32. Epub 2014 Mar 13.
    View PubMed
  60. Valent P, Escribano L, Broesby-Olsen S, Hartmann K, Grattan C, Brockow K, Niedoszytko M, Nedoszytko B, Oude Elberink JNG, Kristensen T, Butterfield JH, Triggiani M, Alvarez-Twose I, Reiter A, Sperr WR, Sotlar K, Yavuz S, Kluin-Nelemans HC, Hermine O, Radia D, Van Doormaal JJ, Gotlib J, Orfao A, Siebenhaar F, Schwartz LB, Castells M, Maurer M, Horny HP, Akin C, Metcalfe DD, Arock M. Proposed diagnostic algorithm for patients with suspected mastocytosis: A proposal of the European Competence Network on Mastocytosis. Allergy: European Journal of Allergy and Clinical Immunology. 2014; 69(10):1267-74.
  61. Butterfield JH, Weiler CR. Presentation of untreated systemic mastocytosis as recurrent, pulseless-electrical-activity cardiac arrests resistant to cardiac pacemaker. Int Arch Allergy Immunol. 2014; 163 (2):130-4 Epub 2013 Dec 04
    View PubMed
  62. Pyle RC, Butterfield JH, Volcheck GW, Podjasek JC, Rank MA, Li JT, Harish A, Poe KL, Park MA. Successful outpatient graded administration of trimethoprim-sulfamethoxazole in patients without HIV and with a history of sulfonamide adverse drug reaction. J Allergy Clin Immunol Pract. 2014 Jan-Feb; 2(1):52-8.
    View PubMed
  63. Pardanani A, Chen D, Abdelrahman RA, Reichard KK, Zblewski D, Wood AJ, McClure RF, Butterfield JH, Hanson CA, Tefferi A. Clonal mast cell disease not meeting WHO criteria for diagnosis of mastocytosis: clinicopathologic features and comparison with indolent mastocytosis. Leukemia 2013 Oct; 27 (10):2091-4 Epub 2013 July 30
    View PubMed
  64. Butterfield JH, Weiler CR. Systemic mastocytosis in the elderly. Am J Hematol. 2013 May; 88(5):406-8. Epub 2013 Mar 27.
    View PubMed
  65. Podjasek JC, Butterfield JH. Mortality in hypereosinophilic syndrome: 19 years of experience at Mayo Clinic with a review of the literature. Leuk Res. 2013 Apr; 37 (4):392-5 Epub 2013 Jan 16
    View PubMed
  66. Valent P, Klion AD, Rosenwasser LJ, Arock M, Bochner BS, Butterfield JH, Gotlib J, Haferlach T, Hellmann A, Horny HP, Leiferman KM, Metzgeroth G, Matsumoto K, Reiter A, Roufosse F, Rothenberg ME, Simon HU, Sotlar K, Vandenberghe P, Weller PF, Gleich GJ. ICON: Eosinophil Disorders. World Allergy Organ J. 2012 Dec; 5 (12):174-81
    View PubMed
  67. Bochner BS, Book W, Busse WW, Butterfield J, Furuta GT, Gleich GJ, Klion AD, Lee JJ, Leiferman KM, Minnicozzi M, Moqbel R, Rothenberg ME, Schwartz LB, Simon HU, Wechsler ME, Weller PF. Workshop report from the National Institutes of Health Taskforce on the Research Needs of Eosinophil-Associated Diseases (TREAD). J Allergy Clin Immunol. 2012 Sep; 130(3):587-96.
    View PubMed
  68. Valent P, Klion AD, Horny HP, Roufosse F, Gotlib J, Weller PF, Hellmann A, Metzgeroth G, Leiferman KM, Arock M, Butterfield JH, Sperr WR, Sotlar K, Vandenberghe P, Haferlach T, Simon HU, Reiter A, Gleich GJ. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol. 2012 Sep; 130(3):607-612.e9. Epub 2012 Mar 28.
    View PubMed
  69. Ritter M, El-Nour H, Hedblad MA, Butterfield JH, Beck O, Stephanson N, Holst M, Giscombe R, Azmitia EC, Nordlind K. Serotonin and its 5-HT1 receptor in human mastocytosis. Immunopharmacol Immunotoxicol. 2012 Aug; 34(4):679-85. Epub 2012 Feb 01.
    View PubMed
  70. Valent P, Gleich GJ, Reiter A, Roufosse F, Weller PF, Hellmann A, Metzgeroth G, Leiferman KM, Arock M, Sotlar K, Butterfield JH, Cerny-Reiterer S, Mayerhofer M, Vandenberghe P, Haferlach T, Bochner BS, Gotlib J, Horny HP, Simon HU, Klion AD. Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field. Expert Rev Hematol. 2012 Apr; 5(2):157-76.
    View PubMed
  71. Butterfield JH, Weiler CR. Treatment of hypereosinophilic syndromes--the first 100 years. Semin Hematol. 2012 Apr; 49 (2):182-91
    View PubMed
  72. Butterfield JH, Weiler CR. Use of pegylated interferon in hypereosinophilic syndrome. Leuk Res. 2012 Feb; 36 (2):192-7 Epub 2011 Nov 26
    View PubMed
  73. Valent P, Akin C, Arock M, Brockow K, Butterfield JH, Carter MC, Castells M, Escribano L, Hartmann K, Lieberman P, Nedoszytko B, Orfao A, Schwartz LB, Sotlar K, Sperr WR, Triggiani M, Valenta R, Horny HP, Metcalfe DD. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol. 2012; 157(3):215-25. Epub 2011 Oct 27.
    View PubMed
  74. Smith JH, Butterfield JH, Cutrer FM. Primary headache syndromes in systemic mastocytosis. Cephalalgia. 2011 Nov; 31(15):1522-31. Epub 2011 Sep 29.
    View PubMed
  75. Smith JH, Butterfield JH, Pardanani A, DeLuca GC, Cutrer FM. Neurologic symptoms and diagnosis in adults with mast cell disease. Clin Neurol Neurosurg. 2011 Sep; 113(7):570-4. Epub 2011 Jun 12.
    View PubMed
  76. Shah KM, Rank MA, Dave SA, Oslie CL, Butterfield JH. Predicting which medication classes interfere with allergy skin testing. Allergy Asthma Proc. 2010 Nov-Dec; 31 (6):477-82
    View PubMed
  77. Butterfield JH. Increased leukotriene E4 excretion in systemic mastocytosis. Prostaglandins Other Lipid Mediat. 2010 Jun; 92(1-4):73-6. Epub 2010 Apr 07.
    View PubMed
  78. Lim KH, Pardanani A, Butterfield JH, Li CY, Tefferi A. Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine. Am J Hematol. 2009 Dec; 84 (12):790-4
    View PubMed
  79. Ogbogu PU, Bochner BS, Butterfield JH, Gleich GJ, Huss-Marp J, Kahn JE, Leiferman KM, Nutman TB, Pfab F, Ring J, Rothenberg ME, Roufosse F, Sajous MH, Sheikh J, Simon D, Simon HU, Stein ML, Wardlaw A, Weller PF, Klion AD. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol. 2009 Dec; 124(6):1319-25.e3.
    View PubMed
  80. Butterfield JH. Success of short-term, higher-dose imatinib mesylate to induce clinical response in FIP1L1-PDGFRalpha-negative hypereosinophilic syndrome. Leuk Res. 2009 Aug; 33 (8):1127-9 Epub 2009 Jan 13
    View PubMed
  81. Lokhandwala JO, Best PJ, Butterfield JH, Skelding KA, Scott T, Blankenship JC, Buckley JW, Berger PB. Frequency of allergic or hematologic adverse reactions to ticlopidine among patients with allergic or hematologic adverse reactions to clopidogrel. Circ Cardiovasc Interv. 2009 Aug; 2(4):348-51. Epub 2009 Jul 22.
    View PubMed
  82. Lim KH, Tefferi A, Lasho TL, Finke C, Patnaik M, Butterfield JH, McClure RF, Li CY, Pardanani A. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood. 2009 Jun 4; 113 (23):5727-36 Epub 2009 Apr 10
    View PubMed
  83. Butterfield JH. Survey of aspirin administration in systemic mastocytosis. Prostaglandins Other Lipid Mediat. 2009 Apr; 88 (3-4):122-4 Epub 2009 Jan 22
    View PubMed
  84. Butterfield JH, Weiler CR. Prevention of mast cell activation disorder-associated clinical sequelae of excessive prostaglandin D(2) production. Int Arch Allergy Immunol. 2008; 147(4):338-43. Epub 2008 Jul 12.
    View PubMed
  85. Ho CL, Lasho TL, Butterfield JH, Tefferi A. Global cytokine analysis in myeloproliferative disorders. Leuk Res. 2007 Oct; 31 (10):1389-92 Epub 2007 Feb 27
    View PubMed
  86. Butterfield JH. Treatment of hypereosinophilic syndromes with prednisone, hydroxyurea, and interferon. Immunol Allergy Clin North Am. 2007 Aug; 27(3):493-518.
    View PubMed
  87. Meyer GK, Neetz A, Brandes G, Tsikas D, Butterfield JH, Just I, Gerhard R. Clostridium difficile toxins A and B directly stimulate human mast cells. Infect Immun. 2007 Aug; 75(8):3868-76. Epub 2007 May 21.
    View PubMed
  88. Vaklavas C, Tefferi A, Butterfield J, Ketterling R, Verstovsek S, Kantarjian H, Pardanani A. 'Idiopathic' eosinophilia with an Occult T-cell clone: prevalence and clinical course. Leuk Res. 2007 May; 31: (5)691-4.
    View PubMed
  89. Yawn BP, Wollan PC, Bertram SL, Lowe D, Butterfield JH, Bonde D, Li JT. Asthma treatment in a population-based cohort: putting step-up and step-down treatment changes in context. Mayo Clin Proc. 2007 Apr; 82(4):414-21.
    View PubMed
  90. Frigas E, Park MA, Matesic D, Bachman KA, Volcheck GW, Gustafson RO, Friedman O, Pallanch JF, Lane JI, Welker KM, Severson RJ, Butterfield JH, Hagan JB, Li JT, Schroeder DR, Kita H. "A pilot, prospective, double blind, placebo-controlled treatment trial with Itraconazole orally in patients with chronic rhinosinusitis and asthma" (vol 119, pg S142, 2007).[Correction] J Allergy Clin Immunol. 2007 Apr; 119(4):1025.
  91. Yamazaki K, Murray JA, Arora AS, Alexander JA, Smyrk TC, Butterfield JH, Kita H. Allergen-specific in vitro cytokine production in adult patients with eosinophilic esophagitis. Dig Dis Sci. 2006 Nov; 51 (11):1934-41 Epub 2006 Sept 29
    View PubMed
  92. Butterfield JH, Kephart GM, Frankson JL. Eosinophilic oophoritis: association with positive Strongyloides stercoralis serology and clinical response to ivermectin. J Pediatr Adolesc Gynecol. 2006 Oct; 19(5):329-32.
    View PubMed
  93. Butterfield JH. Systemic mastocytosis: clinical manifestations and differential diagnosis. Immunol Allergy Clin North Am. 2006 Aug; 26(3):487-513.
    View PubMed
  94. Pardanani A, Ketterling RP, Li CY, Patnaik MM, Wolanskyj AP, Elliott MA, Camoriano JK, Butterfield JH, Dewald GW, Tefferi A. FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. Leuk Res. 2006 Aug; 30: (8)965-70.
    View PubMed
  95. Butterfield JH, Sharkey SW. Control of hypereosinophilic syndrome-associated recalcitrant coronary artery spasm by combined treatment with prednisone, imatinib mesylate and hydroxyurea. Exp Clin Cardiol. 2006 Spring; 11 (1):25-8
    View PubMed
  96. Butterfield JH, Tefferi A, Kozuh GF. Successful treatment of systemic mastocytosis with high-dose interferon-alfa: long-term follow-up of a case. Leuk Res. 2005 Feb; 29(2):131-4.
    View PubMed
  97. Butterfield JH. Interferon treatment for hypereosinophilic syndromes and systemic mastocytosis. Acta Haematol. 2005; 114 (1):26-40
    View PubMed
  98. Hunt LW, Frigas E, Butterfield JH, Kita H, Blomgren J, Dunnette SL, Offord KP, Gleich GJ. Treatment of asthma with nebulized lidocaine: a randomized, placebo-controlled study. J Allergy Clin Immunol. 2004 May; 113(5):853-9.
    View PubMed
  99. Pardanani A, Hoffbrand AV, Pardanani A, Butterfield JH, Tefferi A. Treatment of systemic mast cell disease with 2-chlorodeoxyadenosine. Leuk Res. 2004 Feb; 28 (2):127-31
    View PubMed
  100. Butterfield JH, Li CY. Bone marrow biopsies for the diagnosis of systemic mastocytosis - Is one biopsy sufficient? Am J Clin Pathol. 2004 Feb; 121(2):264-7.
    View PubMed
  101. Pardanani A, Reeder TL, Kimlinger TK, Baek JY, Li CY, Butterfield JH, Tefferi A. Flt-3 and c-kit mutation studies in a spectrum of chronic myeloid disorders including systemic mast cell disease. Leuk Res. 2003 Aug; 27 (8):739-42
    View PubMed
  102. Sundstrom M, Vliagoftis H, Karlberg P, Butterfield JH, Nilsson K, Metcalfe DD, Nilsson G. Functional and phenotypic studies of two variants of a human mast cell line with a distinct set of mutations in the c-kit proto-oncogene. Immunology. 2003 Jan; 108(1):89-97.
    View PubMed
  103. Pardanani A, Baek JY, Li CY, Butterfield JH, Tefferi A. Systemic mast cell disease without associated hematologic disorder: a combined retrospective and prospective study. Mayo Clin Proc. 2002 Nov; 77(11):1169-75.
    View PubMed
  104. Kelkar PS, Butterfield JH, Kalaaji AN. Urticarial vasculitis with asymptomatic chronic hepatitis C infection: Response to doxepin, interferon-alfa, and ribavirin. J Clin Gastroenterol. 2002 Sep; 35(3):281-2.
    View PubMed
  105. Hosoda M, Yamaya M, Suzuki T, Yamada N, Kamanaka M, Sekizawa K, Butterfield JH, Watanabe T, Nishimura H, Sasaki H. Effects of rhinovirus infection on histamine and cytokine production by cell lines from human mast cells and basophils. J Immunol. 2002 Aug 1; 169(3):1482-91.
    View PubMed
  106. Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, Butterfield JH. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet. 2002 May 4; 359(9317):1577-8.
    View PubMed
  107. Butterfield JH, Murray JA. Eosinophilic gastroenteritis and gluten-sensitive enteropathy in the same patient. J Clin Gastroenterol. 2002 May-Jun; 34 (5):552-3
    View PubMed
  108. Kobayashi H, Gleich GJ, Butterfield JH, Kita H. Human eosinophils produce neurotrophins and secrete nerve growth factor on immunologic stimuli. Blood. 2002 Mar 15; 99 (6):2214-20
    View PubMed
  109. Ma YS, Zeng S, Metcalfe DD, Akin C, Dimitrijevic S, Butterfield JH, McMahon G, Longley BJ. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood. 2002 Mar 1; 99(5):1741-4.
    View PubMed
  110. Baek JY, Li CY, Pardanani A, Butterfield JH, Tefferi A. Bone marrow angiogenesis in systemic mast cell disease. J Hematother Stem Cell Res. 2002 Feb; 11(1):139-46.
    View PubMed
  111. Moertel CL, Kazacos KR, Butterfield JH, Kita H, Watterson J, Gleich GJ. Eosinophil-associated inflammation and elaboration of eosinophil-derived proteins in 2 children with raccoon roundworm (Baylisascaris procyonis) encephalitis. Pediatrics. 2001 Nov; 108(5):E93.
    View PubMed
  112. Kelkar PS, Butterfield JH, Teaford HG. Urticaria and angioedema from cyclooxygenase-2 inhibitors. J Rheumatol. 2001 Nov; 28(11):2553-4.
    View PubMed
  113. Butterfield JH. Diverse clinical outcomes of eosinophilic patients with T-cell receptor gene rearrangements: the emerging diagnostic importance of molecular genetics testing. Am J Hematol. 2001 Oct; 68 (2):81-6
    View PubMed
  114. Huttunen M, Hyttinen M, Nilsson G, Butterfield JH, Horsmanheimo M, Harvima IT. Inhibition of keratinocyte growth in cell culture and whole skin culture by mast cell mediators. Exp Dermatol. 2001 Jun; 10(3):184-92.
    View PubMed
  115. Colamorea T, Di Paola R, Macchia F, Guerrese MC, Tursi A, Butterfield JH, Caiaffa MF, Haeggstrom JZ, Macchia L. 5-Lipoxygenase upregulation by dexamethasone in human mast cells. Biochem Biophys Res Commun. 1999 Nov 30; 265(3):617-24.
    View PubMed
  116. Yocum MW, Butterfield JH, Klein JS, Volcheck GW, Schroeder DR, Silverstein MD. Epidemiology of anaphylaxis in Olmsted County: A population-based study. J Allergy Clin Immunol. 1999 Aug; 104 (2 Pt 1):452-6
    View PubMed
  117. Schulman ES, Glaum MC, Post T, Wang Y, Raible DG, Mohanty J, Butterfield JH, Pelleg A. ATP modulates anti-IgE-induced release of histamine from human lung mast cells. Am J Respir Cell Mol Biol. 1999 Mar; 20(3):530-7.
    View PubMed
  118. Volcheck GW, Butterfield JH, Yunginger JW, Klee GG. Elevated serum levels of calcitonin gene-related peptide in Hymenoptera sting-induced anaphylaxis. J Allergy Clin Immunol. 1998 Jul; 102 (1):149-51
    View PubMed
  119. Maeda K, Taniguchi H, Ohno I, Ohtsu H, Yamauchi K, Sakurai E, Tanno Y, Butterfield JH, Watanabe T, Shirato K. Induction of L-histidine decarboxylase in a human mast cell line, HMC-1. Exp Hematol. 1998 Apr; 26(4):325-31.
    View PubMed
  120. Butterfield JH. Response of severe systemic mastocytosis to interferon alpha. Br J Dermatol. 1998 Mar; 138 (3):489-95
    View PubMed
  121. Schumacher U, van Damme EJ, Peumans WJ, Butterfield JH, Mitchell BS. Lectin histochemistry of human leukaemic mast cells (HMC-1) transplanted into severe combined immunodeficient (scid) mice. Acta Histochem. 1998 Feb; 100(1):1-9.
    View PubMed
  122. Yano K, Nakao K, Sayama K, Hamasaki K, Kato Y, Nakata K, Ishii N, Butterfield JH, Galli SJ. The HMC-1 human mast cell line expresses the hepatocyte growth factor receptor c-met. Biochem Biophys Res Commun. 1997 Oct 29; 239(3):740-5.
    View PubMed
  123. Tam SY, Tsai M, Yamaguchi M, Yano K, Butterfield JH, Galli SJ. Expression of functional TrkA receptor tyrosine kinase in the HMC-1 human mast cell line and in human mast cells. Blood. 1997 Sep 1; 90(5):1807-20.
    View PubMed
  124. Yano K, Yamaguchi M, de Mora F, Lantz CS, Butterfield JH, Costa JJ, Galli SJ. Production of macrophage inflammatory protein-1alpha by human mast cells: increased anti-IgE-dependent secretion after IgE-dependent enhancement of mast cell IgE-binding ability. Lab Invest. 1997 Aug; 77(2):185-93.
    View PubMed
  125. Butterfield JH. Hypereosinophilic syndromes. BioDrugs. 1997 May; 7 (5):341-55
    View PubMed
  126. Wedi B, Lewrick H, Butterfield JH, Kapp A. Human HMC-1 mast cells exclusively express the Fc gamma RII subtype of IgG receptor. Arch Dermatol Res. 1996 Dec; 289(1):21-7.
    View PubMed
  127. Jaffe JS, Raible DG, Post TJ, Wang Y, Glaum MC, Butterfield JH, Schulman ES. Human lung mast cell activation leads to IL-13 mRNA expression and protein release. American Journal of Respiratory Cell & Molecular Biology. 1996 Oct; 15(4):473-81.
    View PubMed
  128. Wedi B, Elsner J, Czech W, Butterfield JH, Kapp A. Modulation of intercellular adhesion molecule 1 (ICAM-1) expression on the human mast-cell line (HMC)-1 by inflammatory mediators. Allergy. 1996 Oct; 51(10):676-84.
    View PubMed
  129. Baghestanian M, Agis H, Bevec D, Bankl HC, Hofbauer R, Kress HG, Butterfield JH, Muller MR, Ashman LK, Fureder W, Willheim M, Lechner K, Valent P. Stem cell factor-induced downregulation of c-kit in human lung mast cells and HMC-1 mast cells. Exp Hematol. 1996 Oct; 24(12):1377-86.
    View PubMed
  130. Finotto S, Marshall JS, Butterfield JH, Denburg JA. Specific inhibition of beta-tryptase expression in a human mast cell line by granulocyte-macrophage colony-stimulating factor produced by airways structural cells. American Journal of Respiratory Cell & Molecular Biology. 1996 Sep; 15(3):355-60.
    View PubMed
  131. Werfel T, Oppermann M, Butterfield JH, Begemann G, Elsner J, Gotze O, Zwirner J. The human mast cell line HMC-1 expresses C5a receptors and responds to C5a but not to C5a(desArg). Scand J Immunol. 1996 Jul; 44(1):30-6.
    View PubMed
  132. Love KS, Lakshmanan RR, Butterfield JH, Fox CC. IFN-gamma-stimulated enhancement of MHC class II antigen expression by the human mast cell line HMC-1. Cell Immunol. 1996 May 25; 170(1):85-90.
    View PubMed
  133. Agis H, Fureder W, Bankl HC, Kundi M, Sperr WR, Willheim M, Boltz-Nitulescu G, Butterfield JH, Kishi K, Lechner K, Valent P. Comparative immunophenotypic analysis of human mast cells, blood basophils and monocytes. Immunology. 1996 Apr; 87(4):535-43.
    View PubMed
  134. Ulrich I, Butterfield J, Leiferman K, Li C, Pearson R. A patient with diarrhea, hepatosplenomegaly lymphadenopathy, and a macular rash. Gastroenterology International. 1996; 8(3):101-115.
  135. Molinari JF, Moore WR, Clark J, Tanaka R, Butterfield JH, Abraham WM. Role of tryptase in immediate cutaneous responses in allergic sheep. J Appl Physiol. 1995 Dec; 79(6):1966-1970.
    View PubMed
  136. Fureder W, Agis H, Willheim M, Bankl HC, Maier U, Kishi K, Muller MR, Czerwenka K, Radaszkiewicz T, Butterfield JH. Differential expression of complement receptors on human basophils and mast cells. Evidence for mast cell heterogeneity and CD88/C5aR expression on skin mast cells. J Immunol. 1995 Sep 15; 155(6):3152-60.
    View PubMed
  137. Qu Z, Liebler JM, Powers MR, Galey T, Ahmadi P, Huang XN, Ansel JC, Butterfield JH, Planck SR, Rosenbaum JT. Mast cells are a major source of basic fibroblast growth factor in chronic inflammation and cutaneous hemangioma. Am J Pathol. 1995 Sep; 147(3):564-73.
    View PubMed
  138. Butterfield JH, Gleich GJ. Treatment of the hypereosinophilic syndrome with interferon-alpha. Ann Intern Med. 1995 Jul 15; 123:156.
  139. Macchia L, Hamberg M, Kumlin M, Butterfield JH, Haeggstrom JZ. Arachidonic acid metabolism in the human mast cell line HMC-1: 5-lipoxygenase gene expression and biosynthesis of thromboxane. Biochim Biophys Acta. 1995 Jun 27; 1257(1):58-74.
    View PubMed
  140. Butterfield JH, Kao PC, Klee GC, Yocum MW. Aspirin idiosyncrasy in systemic mast cell disease: a new look at mediator release during aspirin desensitization. Mayo Clin Proc. 1995 May; 70 (5):481-7
    View PubMed
  141. Buckley MG, Williams CM, Thompson J, Pryor P, Ray K, Butterfield JH, Coleman JW. IL-4 enhances IL-3 and IL-8 gene expression in a human leukemic mast cell line. Immunology. 1995 Mar; 84(3):410-5.
    View PubMed
  142. Ulrich CD II, Butterfield JH, Leiferman KM, Li CY, Pearson RK. A patient with diarrhea, hepatosplenomegaly lymphadenopathy, and a macular rash. Gastroenterology International. 1995; 8(3):101-15.
  143. Butterfield JH, Bartley GB. Atypical periorbital xanthogranulomas associated with systemic benign lymphoepithelial lesions. Ophthalmic Plast Reconstr Surg. 1994 Dec; 10 (4):287-92
    View PubMed
  144. Butterfield JH, Gleich GJ. Response of six patients with idiopathic hypereosinophilic syndrome to interferon alfa. J Allergy Clin Immunol. 1994 Dec; 94 (6 Pt 2):1318-26
    View PubMed
  145. Butterfield JH, Gleich GJ. Interferon-alpha treatment of six patients with the idiopathic hypereosinophilic syndrome. Ann Intern Med. 1994 Nov 1; 121 (9):648-53
    View PubMed
  146. Nilsson G, Butterfield JH, Nilsson K, Siegbahn A. Stem cell factor is a chemotactic factor for human mast cells. J Immunol. 1994 Oct 15; 153(8):3717-23.
    View PubMed
  147. Yocum MW, Butterfield JH, Gharib H. Increased plasma calcitonin levels in systemic mast cell disease. Mayo Clin Proc. 1994 Oct; 69 (10):987-90
    View PubMed
  148. Selvan RS, Butterfield JH, Krangel MS. Expression of multiple chemokine genes by a human mast cell leukemia. J Biol Chem. 1994 May 13; 269(19):13893-8.
    View PubMed
  149. Nilsson G, Blom T, Kusche-Gullberg M, Kjellen L, Butterfield JH, Sundstrom C, Nilsson K, Hellman L. Phenotypic characterization of the human mast-cell line HMC-1. Scand J Immunol. 1994 May; 39(5):489-98.
    View PubMed
  150. Kanakura Y, Furitsu T, Tsujimura T, Butterfield JH, Ashman LK, Ikeda H, Kitayama H, Kanayama Y, Matsuzawa Y, Kitamura Y. Activating mutations of the c-kit proto-oncogene in a human mast cell leukemia cell line. Leukemia. 1994 Apr; 8(Suppl 1):S18-22.
    View PubMed
  151. Furitsu T, Tsujimura T, Tono T, Ikeda H, Kitayama H, Koshimizu U, Sugahara H, Butterfield JH, Ashman LK, Kanayama Y. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand- independent activation of c-kit product. J Clin Invest. 1993 Oct; 92(4):1736-44.
    View PubMed
  152. Asano Y, Brach MA, Ahlers A, Vos SD, Butterfield JH, Ashman LK, Valent P, Gruss HJ, Herrmann F. Phorbol ester 12-0-tetradecanoylphorbol-13- acetate down-regulates expression of the c- kit proto-oncogene product. J Immunol. 1993 Sep 1; 151:2345-2354.
    View PubMed
  153. Gauchat JF, Henchoz S, Mazzel G, Aubry JP, Brunner T, Blasey H, Life P, Talabot D, Flores- Romo L, Thompson J, Kishi K, Butterfield JH, Dahinden C, Bonnefoy JY. Induction of human IGE synthesis in B cells by mast cells and basophils. Nature. 1993 Sep; 365:340-343.
    View PubMed
  154. Sillaber C, Bevec D, Butterfield JH, Heppner C, Valenta R, Scheiner O, Kraft D, Lechner K, Bettelheim P, Valent P. Tumor necrosis factor alpha and interleukin-1 beta mRNA expression in HMC-1 cells: differential regulation of gene product expression by recombinant interleukin-4. Exp Hematol. 1993 Aug; 21(9):1271-5.
    View PubMed
  155. Butterfield JH, Leiferman KM, Gleich GJ. Nodules, eosinophilia, rheumatism, dermatitis and swelling (NERDS): a novel eosinophilic disorder. Clin Exp Allergy. 1993 Jul; 23 (7):571-80
    View PubMed
  156. Perez GL, Peters MS, Reda AM, Butterfield JH, Peterson EA, Leiferman KM. Mast cells, neutrophils, and eosinophils in prurigo nodularis. Arch Dermatol. 1993 Jul; 129(7):861-5.
    View PubMed
  157. Caughey GH, Schaumberg TH, Zerweck EH, Butterfield JH, Hanson RD, Silverman GA, Ley TJ. The human mast cell chymase gene (CMA1): mapping to the cathepsin G/granzyme gene cluster and lineage-restricted expression. Genomics. 1993 Mar; 15(3):614-20.
    View PubMed
  158. Hunt LW, Colby TV, Weiler DA, Sur S, Butterfield JH. Immunofluorescent staining for mast cells in idiopathic pulmonary fibrosis: quantification and evidence for extracellular release of mast cell tryptase. Mayo Clin Proc. 1992 Oct; 67 (10):941-8
    View PubMed
  159. Butterfield JH, Leiferman KM, Abrams J, Silver JE, Bower J, Gonchoroff N, Gleich GJ. Elevated serum levels of interleukin-5 in patients with the syndrome of episodic angioedema and eosinophilia. Blood. 1992 Feb 1; 79 (3):688-92
    View PubMed
  160. Sillaber C, Strobl H, Bevec D, Ashman LK, Butterfield JH, Lechner K, Maurer D, Bettelheim P, Valent P. IL-4 regulates c-kit proto-oncogene product expression in human mast and myeloid progenitor cells. J Immunol. 1991 Dec 15; 147(12):4224-8.
    View PubMed
  161. Ten RM, Butterfield JH, Kita H, Weiler DA, Fischkoff S, Ishizaka T, Sanderson CJ, Gleich GJ. Eosinophil differentiation of human umbilical cord mononuclear cells and prolonged survival of mature eosinophils by murine EL-4 thymoma cell conditioned medium. Cytokine. 1991 Jul; 3 (4):350-9
    View PubMed
  162. Valent P, Bevec D, Maurer D, Besemer J, Di Padova F, Butterfield JH, Speiser W, Majdic O, Lechner K, Bettelheim P. Interleukin 4 promotes expression of mast cell ICAM-1 antigen. Proc Natl Acad Sci U S A. 1991 Apr 15; 88(8):3339-42.
    View PubMed
  163. Valent P, Besemer J, Sillaber C, Butterfield JH, Eher R, Majdic O, Kishi K, Klepetko W, Eckersberger F, Lechner K. Failure to detect IL-3-binding sites on human mast cells. J Immunol. 1990 Nov 15; 145(10):3432-7.
    View PubMed
  164. Butterfield JH, Weiler DA, Hunt LW, Wynn SR, Roche PC. Purification of tryptase from a human mast cell line. J Leukoc Biol. 1990 May; 47 (5):409-19
    View PubMed
  165. Butterfield JH, Weiler D, Peterson EA, Gleich GJ, Leiferman KM. Sequestration of eosinophil major basic protein in human mast cells. Lab Invest. 1990 Jan; 62 (1):77-86
    View PubMed
  166. Butterfield JH, Weiler DA. In vitro sensitivity of immature human mast cells to chemotherapeutic agents. Int Arch Allergy Appl Immunol. 1989; 89 (2-3):297-300
    View PubMed
  167. Butterfield JH, Marcoux JP, Weiler D, Harner SG. Mast cell pharyngitis as a cause of supraglottic edema. Arch Otorhinolaryngol. 1988; 245 (2):88-91
    View PubMed
  168. Butterfield JH, Weiler D, Dewald G, Gleich GJ. Establishment of an immature mast cell line from a patient with mast cell leukemia. Leuk Res. 1988; 12 (4):345-55
    View PubMed
  169. Butterfield JH, Kephart GM, Banks PM, Gleich GJ. Extracellular deposition of eosinophil granule major basic protein in lymph nodes of patients with Hodgkin's disease. Blood. 1986 Dec; 68(6):1250-6.
    View PubMed
  170. Butterfield JH, Ackerman SJ, Weiler D, Eisenbrey AB, Gleich GJ. Effects of glucocorticoids on eosinophil colony growth. Journal of Allergy & Clinical Immunology. 1986 Sep; 78(3 Pt 1):450-7.
    View PubMed
  171. Butterfield JH, Weiler D. Giant eosinophil colonies from cultures of bone marrow cells. In Vitro Cellular & Developmental Biology. 1986 Mar; 22(3 Pt 1):157-63.
    View PubMed
  172. Butterfield JH, Schwenk NF, Colville D, Kuipers BJ. Severe generalized reactions to ibuprofen. J Rheumatol. 1986; 13:649-650.
    View PubMed
  173. Maddox DE, Kephart GM, Coulam CB, Butterfield JH, Benirschke K, Gleich GJ. Localization of a molecule immunochemically similar to eosinophil major basic protein in human placenta. J Exp Med. 1984 Jul 1; 160(1):29-41.
    View PubMed
  174. Butterfield JH, Ackerman SJ, Scott RE, Pierre RV, Gleich GJ. Evidence for secretion of human eosinophil granule major basic protein and Charcot-Leyden crystal protein during eosinophil maturation. Exp Hematol. 1984 Mar; 12(3):163-70.
    View PubMed
  175. Maddox DE, Butterfield JH, Ackerman SJ, Coulam CB, Gleich GJ. Elevated serum levels of eosinophil granule major basic protein in human pregnancy. Basic protein. J Exp Med. 1983 Oct 1; 158:1211-1226.
    View PubMed
  176. Welsh PW, Butterfield JH, Yunginger JW, Agarwal MK, Gleich GJ. Allergen-controlled study of intranasal immunotherapy for ragweed hay fever. Journal of Allergy & Clinical Immunology. 1983 May; 71(5):454-60.
    View PubMed
  177. Butterfield JH, Maddox DE, Gleich GJ. The eosinophil leukocyte: maturation and function. Clin Immunol Rev. 1983-84; 2(2):187-306.
  178. Butterfield JH, Eisenbrey AB, Gleich GJ. Membrane marker characterization of the eosinophil colony-forming cell. Br J Haematol. 1982 Jun; 51(2):209-16.
    View PubMed
  179. Butterfield JH, Gleich GJ, Yunginger JW, Zimmermann EM, Reed CE. Immunotherapy with short ragweed fraction A:D-glutamic acid:D-lysine polymer in ragweed hay fever. Journal of Allergy & Clinical Immunology. 1981 Apr; 67(4):272-8.
    View PubMed
PST-20218057